Pleiotropic effects of the non-calcium phosphate binder sevelamer
✍ Scribed by Nikolov, I G; Joki, N; Maizel, J; Lacour, B; Drüeke, T B; Massy, Z A
- Book ID
- 110053288
- Publisher
- Nature Publishing Group
- Year
- 2006
- Tongue
- English
- Weight
- 132 KB
- Volume
- 70
- Category
- Article
- ISSN
- 0085-2538
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective Gout affects a large fraction of persons with advanced chronic kidney disease, and hyperuricemia may increase the risk of cardiovascular disease. Several hypouricemic agents are contraindicated in patients with end‐stage renal disease. Sevelamer is a nonabsorbed hydrogel t
The high tablet burden and poor compliance associated with phosphate-binding drugs has led to a search for more potent agents. In vitro-binding studies were performed on the recently introduced binder, lanthanum carbonate (LC; Fosrenol), to compare its phosphate-binding affinity with sevelamer hydro
## Abstract Six different tetracalcium phosphate (TTCP) products were synthesized by solid state reaction at high temperature by varying the overall calcium to phosphate ratio of the synthesis mixture. The objective was to evaluate the effect of the calcium to phosphate ratio on a TTCP‐dicalcium ph